Forte Biosciences Inc (FBRX)
0.745
+0.02
(+2.41%)
USD |
NASDAQ |
May 10, 16:00
0.73
-0.02
(-2.01%)
Pre-Market: 20:00
Forte Biosciences Net Income (Quarterly): -5.872M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.872M |
| September 30, 2023 | -9.955M |
| June 30, 2023 | -8.896M |
| March 31, 2023 | -6.753M |
| December 31, 2022 | -4.877M |
| September 30, 2022 | -3.40M |
| June 30, 2022 | -3.035M |
| March 31, 2022 | -2.567M |
| December 31, 2021 | -3.341M |
| Date | Value |
|---|---|
| September 30, 2021 | -7.751M |
| June 30, 2021 | -5.812M |
| March 31, 2021 | -4.804M |
| December 31, 2020 | -4.576M |
| September 30, 2020 | -5.10M |
| June 30, 2020 | -34.76M |
| March 31, 2020 | -2.05M |
| September 30, 2019 | -0.69M |
| June 30, 2019 | -0.63M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-34.76M
Minimum
Jun 2020
-0.63M
Maximum
Jun 2019
-6.382M
Average
-4.840M
Median
Net Income (Quarterly) Benchmarks
| CEL-SCI Corp | -6.710M |
| AIM ImmunoTech Inc | -12.58M |
| IGC Pharma Inc | -5.589M |
| NovaBay Pharmaceuticals Inc | -4.108M |
| Protalix BioTherapeutics Inc | -6.044M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.381M |
| EPS Diluted (Quarterly) | -0.04 |
| Enterprise Value | -10.01M |
| Earnings Yield | -139.6% |